Cargando…
1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
BACKGROUND: Antimicrobial dosing in moderate/severe burns patients is complicated due to the potential unpredictable hyperdynamic pathophysiologic states including 1) hypoproteinemia, 2) acute kidney injury and 3) onset of septicemia. Therefore, distribution assumptions about the population pharmaco...
Autores principales: | Hall, Ronald G, Pasipanodya, Jotam, Putnam, William C, Griswold, John, Dissanaike, Sharmila, Kallem, Raja Reddy, Edpuganti, Vindhya, Subramaniyan, Indhumathy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776551/ http://dx.doi.org/10.1093/ofid/ofaa439.1501 |
Ejemplares similares
-
Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022) -
Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022) -
Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction
por: Sime, Fekade B., et al.
Publicado: (2019) -
Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
por: Mané, Camille, et al.
Publicado: (2020) -
Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)